Percutaneous contrast-enhanced ultrasound-guided transabdominal sac embolization is an effective technique for treating complicated type II endoleaks after endovascular aneurysm repair.

OBJECTIVE: In the present study, we evaluated and compared the outcomes of transarterial embolization with those of percutaneous contrast-enhanced ultrasound-guided transabdominal sac embolization (PUSE) for type II endoleaks (T2ELs). METHODS: A retrospective review was conducted of consecutive patients who had undergone T2EL embolization between January 2015 and December 2020 at our center. The cohort was divided into two groups according to the embolization approach: PUSE vs transarterial. Freedom from aneurysm growth, safety, immediate technical success, freedom from persistent T2ELs, and the repeat embolization rate were assessed. RESULTS: A total of 25 patients and 28 embolization procedures (PUSE, n = 16; transarterial embolization, n = 12) were examined. Both the fluoroscopic time (13.3 ± 3.2 minutes vs 35.0 ± 7.0 minutes; P < .001) and the procedural time (84.9 ± 8.4 minutes vs 117.1 ± 14.8 minutes; P < .001) were significantly shorter in the PUSE group than in the transarterial group. After the embolization procedure, the patients were followed up for a mean duration of 24.7 ± 14.9 months for the PUSE group and 35.9 ± 21.1 months for the transarterial group (P = .1323). Five patients in the transarterial group had undergone unsuccessful embolization, with success in 7 of the 12 patients in the transarterial group and all 16 patients in the PUSE group (P = .0081). Failure had resulted from failed transarterial access or a recurrent T2EL. Three of the five patients had undergone subsequent PUSE during follow-up. No patient in the PUSE group had experienced sac expansion compared with four patients in the transarterial group (P = .0242). Similarly, no patient in the PUSE group had developed a newly discovered T2EL vs four patients in the transarterial group (P = .0242). Thus, the outcomes were markedly better for the PUSE group than were those for the transarterial group. A major procedure-related complication (abdominal abscess) occurred in one patient in the transarterial group. CONCLUSIONS: PUSE is safe and effective for managing T2ELs. It yields better outcomes in terms of preventing aneurysm growth, decreasing the incidence of repeat embolization and complications, minimizing the recurrence of T2ELs, and reducing the fluoroscopic and procedural times. We, thus, regard it as the preferred approach for the management of T2ELs.

In Vitro Inhibitory Effects of Agarwood Tea (Aquilaria malaccensis Lamk) Aqueous Extract on Human Cytochrome P450 (CYP) Enzyme Activities.

BACKGROUND: Agarwood tea derived from Aquilaria malaccensis Lamk is becoming an increasingly popular herbal drink that is said to have multiple health benefits. Co-administration of this tea and clinical used drugs is possible, but it increases the risk of drug-herb interactions. OBJECTIVE: This in vitro study investigated the inhibitory effects of agarwood tea aqueous extract on the eight major human drug-metabolising cytochrome P450 (CYP) enzyme activities. METHODS: High-throughput fluorescence-based Vivid® CYP450 screening kits were employed to obtain the enzyme activities before and after incubation with agarwood tea aqueous extract. RESULTS: Agarwood aqueous extract potently inhibited CYP2C9, CYP2D6, and CYP3A4 activities with Ki values of 5.1, 34.5, and 20.3µg/ml, respectively. The most likely inhibition mode responsible for these inhibitions was non-competitive inhibition. On the other hand, at 1000µg/ml, agarwood tea aqueous extract negligibly inhibited CYP1A2, CYP2B6, CYP2C19, CYP2E1, and CYP3A5 activities. CONCLUSION: These findings can be used to design additional in vitro investigations using clinical relevant drug substrates for CYP2C9, CYP2D6, and CYP3A4. Subsequently, future studies can be conducted to determine potential interactions between agarwood tea aqueous extract and CYP using in vivo models.

Retraction notice to "Role of hepatic neuropeptide Y-Y1 receptors in a methionine- cholinedeficient model of non-alcoholic steatohepatitis" [Life Sci. 245 (2020) 117356].

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This article has been retracted at the request of the Editor-in-Chief. Concern has been raised by a reader about both the inappropriateness of certain methods used to prepare Figures 1A and 3A; as well as the lack of important information including the exact age of the mice and details of the ELISA used. These issues could undermine the scientific grounds of the article. Apologies are offered to readers of the journal that this was not detected during the submission process.

Heteroatom Doping Strategy for Establishing Hematite Homojunction as Efficient Photocatalyst for Accelerating Water Splitting.

Hematite (α-Fe2 O3 ) is one of the promising photocatalysts for water oxidation, owing to its stable, abundant and visible-light responsive features. Enhancing electrical conductivity and accelerating oxidation evolution kinetics are expected to improve photocatalytic ability of hematite toward water oxidation. In this work, strategies of doping heteroatoms and developing pn homojunction are adopted to enhance the photocatalytic ability of hematite electrodes. The Ti and Mg dopants are separately incorporated in two layers of hematite electrodes via two-step hydrothermal reaction and one-step annealing process. The effect of regrowth time for synthesizing Mg-doped hematite on the photoelectrochemical performance of Mg-doped and Ti-doped hematite (Mg-Fe2 O3 /Ti-Fe2 O3 ) electrode is studied. The size of rod-like structure and gaps in-between play important roles on the photocatalytic ability of Mg-Fe2 O3 /Ti-Fe2 O3 . The optimized Mg-Fe2 O3 /Ti-Fe2 O3 electrode is prepared by using merely 10 min for synthesizing the Mg-doped hematite top layer, which shows the highest photocurrent density of 2.83 mA/cm2 at 1.60 VRHE along with the highest carrier density of 5.89×1016  cm-3 and the smallest charge-transfer resistance. This largely improved photoelectrochemical performance is attributed to the more donor generation with heteroatom-doping and more efficient charge cascade with homojunction establishment. Other p-type metals are encouraged to dope in hematite as the second layer to couple with the n-type Ti-doped hematite for developing efficient pn homojunction and improve the photocatalytic ability of hematite in the near future.